Shield’s FY 2020 results contained few surprises, given the trading update that accompanied its fundraising in February. Revenues of £10.4m included £9.7m of milestones, which included grossed-up £1m withholding tax on ASK Pharm’s upfront milestone and royalties from Norgine of £0.7m. Net cash at 31 March following February’s fundraising was £28.2m, providing the necessary resources to fund the launch of Accrufer in the US and complete Feraccru’s paediatric study and early formulation work for P ....
29 Apr 2021
Shield Therapeutics - FY 2020 results – targeting US Accrufer launch in June
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - FY 2020 results – targeting US Accrufer launch in June
Shield Therapeutics Plc (STX:LON) | 1.5 0 (-3.7%) | Mkt Cap: 11.5m
- Published:
29 Apr 2021 -
Author:
Mark Brewer | Cavendish Research -
Pages:
14
Shield’s FY 2020 results contained few surprises, given the trading update that accompanied its fundraising in February. Revenues of £10.4m included £9.7m of milestones, which included grossed-up £1m withholding tax on ASK Pharm’s upfront milestone and royalties from Norgine of £0.7m. Net cash at 31 March following February’s fundraising was £28.2m, providing the necessary resources to fund the launch of Accrufer in the US and complete Feraccru’s paediatric study and early formulation work for P ....